FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2931064118> ?p ?o ?g. }

• W2931064118 endingPage "a003665" @default.
• W2931064118 startingPage "a003665" @default.
• W2931064118 abstract "KRAS G12D-mutant/p53-deficient non-small-cell lung cancer (NSCLC) models are dependent on the NF-κB pathway that can be down-regulated by the proteasome inhibitor bortezomib. Two exceptional responders were observed on prior clinical trials of bortezomib, both of whom had KRAS G12D-mutant NSCLC, prompting the initiation of this single-center phase 2 trial. Patients with advanced KRAS G12D-mutant NSCLC were eligible. Bortezomib was administered at 1.3 mg/m2 subcutaneously (days 1, 4, 8, 11; 21-d cycle) until progression or unacceptable toxicity. The primary objective was best objective response (RECIST v1.1). Sixteen patients with KRAS G12D-mutant lung adenocarcinomas were treated. Patients had a median pack year smoking history of 4 (range 0-45). A partial response (PR) was observed in one patient (-66% from baseline) and stable disease in five patients on the first stage of this study (overall response rate of 6%, 95% CI: 0.2-30.2), and further patients were not accrued. The median progression-free survival was 1 mo (95% CI: 1-6). The median overall survival was 13 mo (95% CI: 6-NA). The most common treatment-related adverse events were fatigue (38%) and diarrhea (26%). TP53 status did not predict response on exploratory testing. Of note, the patient with a PR had a unique subtype of lung adenocarcinoma-invasive mucinous adenocarcinomas (IMA)-and had rapid clinical improvement and substantial disease regression, which was also previously observed in two other patients with advanced KRAS G12D-mutant lung cancer with IMAs who received bortezomib on separate clinical trials. Exceptional responses to bortezomib can be achieved in KRAS G12D-mutant NSCLCs. KRAS G12D mutation alone, however, is not a robust predictor of response. Further evaluation should only be performed after further elucidation of other factors such as co-occurring alterations and histologic subtype such as IMA that may predict sensitivity to therapy." @default.
• W2931064118 created "2019-04-11" @default.
• W2931064118 creator A5012346270 @default.
• W2931064118 creator A5014837967 @default.
• W2931064118 creator A5018725486 @default.
• W2931064118 creator A5018978653 @default.
• W2931064118 creator A5023532213 @default.
• W2931064118 creator A5033481886 @default.
• W2931064118 creator A5035120516 @default.
• W2931064118 creator A5039791495 @default.
• W2931064118 creator A5039978923 @default.
• W2931064118 creator A5046345178 @default.
• W2931064118 creator A5047053195 @default.
• W2931064118 creator A5053263729 @default.
• W2931064118 creator A5054353657 @default.
• W2931064118 creator A5060033755 @default.
• W2931064118 creator A5062853695 @default.
• W2931064118 creator A5063199354 @default.
• W2931064118 creator A5075461435 @default.
• W2931064118 creator A5078938585 @default.
• W2931064118 date "2019-04-01" @default.
• W2931064118 modified "2023-10-13" @default.
• W2931064118 title "Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with <i>KRAS</i> G12D-mutant lung cancers" @default.
• W2931064118 cites W1772903887 @default.
• W2931064118 cites W1971240021 @default.
• W2931064118 cites W1994225895 @default.
• W2931064118 cites W2009931781 @default.
• W2931064118 cites W2033737920 @default.
• W2931064118 cites W2045509446 @default.
• W2931064118 cites W2065477010 @default.
• W2931064118 cites W2123879591 @default.
• W2931064118 cites W2125194042 @default.
• W2931064118 cites W2145411470 @default.
• W2931064118 cites W2166749501 @default.
• W2931064118 cites W2169183166 @default.
• W2931064118 cites W2342639474 @default.
• W2931064118 cites W2742802588 @default.
• W2931064118 cites W2767162493 @default.
• W2931064118 cites W2890333384 @default.
• W2931064118 cites W961324200 @default.
• W2931064118 doi "https://doi.org/10.1101/mcs.a003665" @default.
• W2931064118 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6549573" @default.
• W2931064118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30936194" @default.
• W2931064118 hasPublicationYear "2019" @default.
• W2931064118 type Work @default.
• W2931064118 sameAs 2931064118 @default.
• W2931064118 citedByCount "21" @default.
• W2931064118 countsByYear W29310641182019 @default.
• W2931064118 countsByYear W29310641182020 @default.
• W2931064118 countsByYear W29310641182021 @default.
• W2931064118 countsByYear W29310641182022 @default.
• W2931064118 countsByYear W29310641182023 @default.
• W2931064118 crossrefType "journal-article" @default.
• W2931064118 hasAuthorship W2931064118A5012346270 @default.
• W2931064118 hasAuthorship W2931064118A5014837967 @default.
• W2931064118 hasAuthorship W2931064118A5018725486 @default.
• W2931064118 hasAuthorship W2931064118A5018978653 @default.
• W2931064118 hasAuthorship W2931064118A5023532213 @default.
• W2931064118 hasAuthorship W2931064118A5033481886 @default.
• W2931064118 hasAuthorship W2931064118A5035120516 @default.
• W2931064118 hasAuthorship W2931064118A5039791495 @default.
• W2931064118 hasAuthorship W2931064118A5039978923 @default.
• W2931064118 hasAuthorship W2931064118A5046345178 @default.
• W2931064118 hasAuthorship W2931064118A5047053195 @default.
• W2931064118 hasAuthorship W2931064118A5053263729 @default.
• W2931064118 hasAuthorship W2931064118A5054353657 @default.
• W2931064118 hasAuthorship W2931064118A5060033755 @default.
• W2931064118 hasAuthorship W2931064118A5062853695 @default.
• W2931064118 hasAuthorship W2931064118A5063199354 @default.
• W2931064118 hasAuthorship W2931064118A5075461435 @default.
• W2931064118 hasAuthorship W2931064118A5078938585 @default.
• W2931064118 hasBestOaLocation W29310641181 @default.
• W2931064118 hasConcept C121608353 @default.
• W2931064118 hasConcept C126322002 @default.
• W2931064118 hasConcept C143998085 @default.
• W2931064118 hasConcept C2776256026 @default.
• W2931064118 hasConcept C2776364478 @default.
• W2931064118 hasConcept C2777478702 @default.
• W2931064118 hasConcept C2778822529 @default.
• W2931064118 hasConcept C2779134260 @default.
• W2931064118 hasConcept C2779984678 @default.
• W2931064118 hasConcept C2781182431 @default.
• W2931064118 hasConcept C2781187634 @default.
• W2931064118 hasConcept C31760486 @default.
• W2931064118 hasConcept C526805850 @default.
• W2931064118 hasConcept C535046627 @default.
• W2931064118 hasConcept C71924100 @default.
• W2931064118 hasConceptScore W2931064118C121608353 @default.
• W2931064118 hasConceptScore W2931064118C126322002 @default.
• W2931064118 hasConceptScore W2931064118C143998085 @default.
• W2931064118 hasConceptScore W2931064118C2776256026 @default.
• W2931064118 hasConceptScore W2931064118C2776364478 @default.
• W2931064118 hasConceptScore W2931064118C2777478702 @default.
• W2931064118 hasConceptScore W2931064118C2778822529 @default.
• W2931064118 hasConceptScore W2931064118C2779134260 @default.
• W2931064118 hasConceptScore W2931064118C2779984678 @default.
• W2931064118 hasConceptScore W2931064118C2781182431 @default.
• W2931064118 hasConceptScore W2931064118C2781187634 @default.

• next